The Global Rheumatic-Heart Disease Management Industry is expected to reach US$2.04 billion by 2033. From a value of US$1.31 billion in 2023, this represents a consistent growth, indicating a compound annual growth rate (CAGR) of 4.5%. The continuous advancements in biotechnology and pharmaceuticals, which signal a paradigm shift in the healthcare sector, are credited with this …